Use of risk stratification to target therapies in patients with recent onset arthritis; Design of a prospective randomized multicenter controlled trial

BMC Musculoskeletal Disorders

Volumn 10, Issue 1, 2009, Pages

  Claessen, Susanne J J ^a   Hazes, Johanna M W ^a   Huisman, Margriet A M ^b   Van Zeben, Derkjen ^b   Luime, Jolanda J ^a   Weel, Angelique E A M ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

^c Maasstad Hospital Rotterdam   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CALCIUM; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE ACETATE; NAPROXEN; PREDNISONE; RISEDRONIC ACID; RITUXIMAB; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; VITAMIN D; ANTIRHEUMATIC AGENT;

ADULT; ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MONOTHERAPY; MULTICENTER STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOLOGY; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT DURATION; CLINICAL PROTOCOL; DRUG COMBINATION; DRUG COST; EARLY DIAGNOSIS; HOSPITALIZATION; LONGITUDINAL STUDY; METHODOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STANDARD; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG COSTS; EARLY DIAGNOSIS; HUMANS; LONGITUDINAL STUDIES; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 68149116021     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-10-71     Document Type: Article

References (39)

1. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. KW Drossaers-Bakker M de Buck D van Zeben AH Zwinderman FC Breedveld JM Hazes, Arthritis Rheum 1999 42 9 1854 1860 (Pubitemid 30257749)
2. Radiographic damage of large joints in long-term rheumatoid arthritis and its relation to function. KW Drossaers-Bakker HM Kroon AH Zwinderman FC Breedveld JM Hazes, Rheumatology (Oxford) 2000 39 9 998 1003
3. Clear associations between demographic and psychosocial factors and health-related quality of life in patients with early inflammatory joint complaints. GA Geuskens A Burdorf AW Evers JM Hazes, J Rheumatol 2008 35 9 1754 1761
4. Predictors of sick leave and reduced productivity at work among persons with early inflammatory joint conditions. GA Geuskens JM Hazes PJ Barendregt A Burdorf, Scand J Work Environ Health 2008 34 6 420 429
5. Work and sick leave among patients with early inflammatory joint conditions. GA Geuskens JM Hazes PJ Barendregt A Burdorf, Arthritis Rheum 2008 59 10 1458 1466
6. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study. J Jantti K Aho K Kaarela H Kautiainen, Rheumatology (Oxford) 1999 38 11 1138 1141 (Pubitemid 29537337)
7. The impact of rheumatoid arthritis on life activities. PP Katz, Arthritis Care Res 1995 8 4 272 278 (Pubitemid 26021961)
8. Epidemiology of the Rheumatic Diseases Second Edition. A Silman M Hochberg eds, Oxford: Oxford University Press 2001
9. Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. TW Huizinga KP Machold FC Breedveld PE Lipsky JS Smolen, Arthritis Rheum 2002 46 5 1155 1159
10. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. M Boers AC Verhoeven HM Markusse MA van de Laar R Westhovens JC van Denderen D van Zeben BA Dijkmans AJ Peeters P Jacobs, Lancet 1997 350 9074 309 318 (Pubitemid 27351112)
11. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. M Calguneri S Pay Z Caliskaner S Apras S Kiraz I Ertenli V Cobankara, Clin Exp Rheumatol 1999 17 6 699 704
12. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. KE Donahue G Gartlehner DE Jonas LJ Lux P Thieda BL Jonas RA Hansen LC Morgan KN Lohr, Ann Intern Med 2008 148 2 124 134 (Pubitemid 351651555)
13. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. G Gartlehner RA Hansen BL Jonas P Thieda KN Lohr, J Rheumatol 2006 33 12 2398 2408 (Pubitemid 46067817)
14. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. YP Goekoop-Ruiterman JK de Vries-Bouwstra CF Allaart D van Zeben PJ Kerstens JM Hazes AH Zwinderman AJ Peeters JM de Jonge-Bok C Mallee, Ann Intern Med 2007 146 6 406 415 (Pubitemid 351650575)
15. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. YP Goekoop-Ruiterman JK de Vries-Bouwstra CF Allaart D van Zeben PJ Kerstens JM Hazes AH Zwinderman HK Ronday KH Han ML Westedt, Arthritis Rheum 2005 52 11 3381 3390 (Pubitemid 41612204)
16. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. LR Lard H Visser I Speyer IE vander Horst-Bruinsma AH Zwinderman FC Breedveld JM Hazes, Am J Med 2001 111 6 446 451 (Pubitemid 33016415)
17. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. T Mottonen P Hannonen M Leirisalo-Repo M Nissila H Kautiainen M Korpela L Laasonen H Julkunen R Luukkainen K Vuori, Lancet 1999 353 9164 1568 1573 (Pubitemid 29219206)
18. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. VP Nell KP Machold G Eberl TA Stamm M Uffmann JS Smolen, Rheumatology (Oxford) 2004 43 7 906 914 (Pubitemid 38996967)
19. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. JR O'Dell CE Haire N Erikson W Drymalski W Palmer PJ Eckhoff V Garwood P Maloley LW Klassen S Wees, N Engl J Med 1996 334 20 1287 1291 (Pubitemid 26138009)
20. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. JR O'Dell R Leff G Paulsen C Haire J Mallek PJ Eckhoff A Fernandez K Blakely S Wees J Stoner, Arthritis Rheum 2002 46 5 1164 1170 (Pubitemid 34525821)
21. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey. A Saraux V Devauchelle-Pensec L Engerran RM Flipo, J Rheumatol 2006 33 7 1258 1265 (Pubitemid 44025138)
22. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. SM van der Kooij YP Goekoop-Ruiterman JK de Vries-Bouwstra M Guler-Yuksel AH Zwinderman PJ Kerstens PA van der Lubbe WM de Beus BA Grillet HK Ronday, Ann Rheum Dis 2009 68 6 914 921
23. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper LA Healey SR Kaplan MH Liang HS Luthra, Arthritis Rheum 1988 31 3 315 324 (Pubitemid 18091653)
24. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). B Combe R Landewe C Lukas HD Bolosiu F Breedveld M Dougados P Emery G Ferraccioli JM Hazes L Klareskog, Ann Rheum Dis 2007 66 1 34 45 (Pubitemid 46044858)
25. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. AH van der Helm-van Mil S le Cessie H van Dongen FC Breedveld RE Toes TW Huizinga, Arthritis Rheum 2007 56 2 433 440 (Pubitemid 46271969)
26. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. H Visser S le Cessie K Vos FC Breedveld JM Hazes, Arthritis Rheum 2002 46 2 357 365 (Pubitemid 34136572)
27. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. MF Bakker JW Jacobs SM Verstappen JW Bijlsma, Ann Rheum Dis 2007 66 Suppl 3 iii56 60
28. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. DM van der Heijde MA van't Hof PL van Riel LA Theunisse EW Lubberts MA van Leeuwen MH van Rijswijk LB van de Putte, Ann Rheum Dis 1990 49 11 916 920 (Pubitemid 20360757)
29. Switching anti-TNF-alpha agents: what is the evidence? AR Erickson TR Mikuls, Curr Rheumatol Rep 2007 9 5 416 420 (Pubitemid 47597063)
30. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. KL Hyrich M Lunt KD Watson DP Symmons AJ Silman, Arthritis Rheum 2007 56 1 13 20 (Pubitemid 46106174)
31. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. RF van Vollenhoven, Ann Rheum Dis 2007 66 7 849 851 (Pubitemid 46999781)
32. Measurement of disability in Dutch rheumatoid arthritis patients. CE Siegert LJ Vleming JP Vandenbroucke A Cats, Clin Rheumatol 1984 3 3 305 309 (Pubitemid 15072110)
33. How to read radiographs according to the Sharp/van der Heijde method. D van der Heijde, J Rheumatol 1999 26 3 743 745 (Pubitemid 29125603)
34. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. DT Felson JJ Anderson M Boers C Bombardier M Chernoff B Fried D Furst C Goldsmith S Kieszak R Lightfoot, Arthritis Rheum 1993 36 6 729 740
35. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. AM van Gestel ML Prevoo MA van't Hof MH van Rijswijk LB van de Putte PL van Riel, Arthritis Rheum 1996 39 1 34 40 (Pubitemid 26036375)
36. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. G Stucki MH Liang S Stucki P Bruhlmann BA Michel, Arthritis Rheum 1995 38 6 795 798
37. EuroQola new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990 16 3 199 208
38. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. NK Aaronson M Muller PD Cohen ML Essink-Bot M Fekkes R Sanderman MA Sprangers A te Velde E Verrips, J Clin Epidemiol 1998 51 11 1055 1068 (Pubitemid 28527161)
39. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. MT Nurmohamed BA Dijkmans, Drugs 2005 65 5 661 694 (Pubitemid 40477785)